Biomarkers for the detection of bladder cancer

Advances in Anatomic Pathology

Volumn 8, Issue 1, 2001, Pages 37-45

  Ross, Jeffrey S ^a   Cohen, Michael B ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Biomarkers; Bladder cancer; Prognostic factors

Indexed keywords

DNA; MICROSATELLITE DNA; TELOMERASE; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; BLADDER TUMOR; CHEMISTRY; COMPARATIVE STUDY; CYTODIAGNOSIS; EVALUATION; HUMAN; PATHOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; UROTHELIUM;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CYTODIAGNOSIS; DNA, NEOPLASM; HUMANS; MICROSATELLITE REPEATS; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0035219620     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200101000-00006     Document Type: Review

References (115)

1. Landis, SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. Ca-A Cancer J Clin 1999;49:8-31.
2. Foresman WH, Messing, EM. Bladder cancer: natural history, tumor markers, and early detection strategies. Sem Surg Oncol 1997;13:299-306. (Pubitemid 27332852)
3. Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O. Urine cytology, tumor markers and bladder cancer. Br J Urol 1998;82:647-54. (Pubitemid 28497747)
4. Lynch CF, Cohen MB. Urinary system. Cancer (suppl) 1995;75:316-9.
5. Koss LG. Diagnostic cytology of the urinary tract. Philadelphia: JB Lippincott, 1995.
6. Rosenthal DL. Urologic cytology. In Astarita RWED, ed. Practical cytopathology. New York: Churchill Livingstone, 1990:303-36.
7. Shenoy UA, Colby TV, Schumann GB. Reliability of urinary cytodiagnosis in urothelial neoplasms. Cancer 1985;56:2041-5. (Pubitemid 15240881)
8. Raab SS, Lenel JC, Cohen MB. Low grade transitional cell carcinoma of the bladder. Cytologic diagnosis by key features as identified by logistic regression analysis. Cancer 1994;74:1621-6. (Pubitemid 24302985)
9. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995;48:314-7.
10. Hughes JH, Raab SS, Cohen MB. The cytologic diagnosis of low-grade transitional cell carcinoma (review). Pathol:Cytopathol 1999 (in press).
11. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990;21:886-96. (Pubitemid 20308410)
12. Raab, SS, Slagel DD, Jensen CS, et al. Transitional cell carcinoma: cytologic criteria to improve diagnostic accuracy. Mod Pathol 1996;9:225-32. (Pubitemid 26126547)
13. Tut VM, Hildreth AJ, Kumar M, Mellon JK. Does voided urine cytology have biological significance? Br J Urol 1998;82:655-9. (Pubitemid 28497748)
14. Wiener HG, Mian CH, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80. (Pubitemid 29190716)
15. Pirtskalaishvili G, Getzenberg RH, Konety BR. Use of urine-based markers for detection and monitoring bladder cancer. Tech Urol 1999;5(4):179-84.
16. Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin N Am 2000;27:25-37. (Pubitemid 30085995)
17. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-83.
18. D'Hallewin MA, Baert L. Initial evaluation of the bladder tumor antigen test and superficial bladder cancer. J Urol 1996;155:475-6. (Pubitemid 26023527)
19. Ianari A, Sternberg CN, Rossetti A, et al. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology 1997;49:786-9. (Pubitemid 27194603)
20. Leyh H, Mazeman E. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997;32:425-8. (Pubitemid 27501040)
21. Miyanaga N, Akaza H, Kameyama S, et al. Significance of the BTA test in bladder cancer: a multicenter trial. Int J Urol 1997;4:557-60. (Pubitemid 28021293)
22. Van der Poel HG, Van Balken MR, Schamhart DH, et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998;51:44-50. (Pubitemid 28092504)
23. Zimmerman RL, Bagley D, Hawthorne C, Bibbo M. Utility of the Bard BTA test in detecting upper urinary tract transitional cell carcinoma. Urology 1998;51:956-8. (Pubitemid 28240855)
24. Abbate I, D'Introno A, Cardo G, et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998;18:3803-5. (Pubitemid 28564270)
25. Schamhart DH, de Reijke TM, van der Poel HG, et al. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. Eur Urol 1998;34:99-106. (Pubitemid 28398458)
26. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.
27. Nasuti JF, Gomella LG, Ismail M, Bibbo M. Utility of the BTA Stat Test Kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-9. (Pubitemid 29294047)
28. Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000;27(1):63-73. (Pubitemid 30085999)
29. Hughes JH, Cohen MB. Nuclear matrix proteins and their potential applications to diagnostic pathology. Am J Clin Pathol 1999;111:267-74. (Pubitemid 29054957)
30. Soloway MS, Briggman V, Carpinito GA, et al. Use of new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7. (Pubitemid 126445343)
31. Miyanage N, Akaza H, Ishikawa S, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997;31:163-8. (Pubitemid 27101701)
32. Witjes JA, va der Poel HG, van Balken MR, Debruyne FM, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998;33:387-91. (Pubitemid 28230263)
33. Serretta A, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998;52:793-6. (Pubitemid 28489703)
34. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998;159:394-8. (Pubitemid 28049240)
35. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402. (Pubitemid 28399904)
36. Sozen S, Biri H, Sinik Z, Kupeli B, Alkibay T, Bozkirli I. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999;36(3):225-9. (Pubitemid 29381309)
37. Hughes JH, Katz RL, Rodriguez-Villanueva J, et al. Urinary matrix protein 22 (NMP 22): examination for the detection of recurrent transitional cell-carcinoma of the bladder. Diagn Cytopathol 1999;20:285-90. (Pubitemid 29205522)
38. Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999;19(4A):2621-3. (Pubitemid 29392423)
39. Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors: diagnostic utility and clinical applications. Am J Clin Pathol 1999;112(Suppl):S68-S75. (Pubitemid 30219465)
40. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998;4:1949-54. (Pubitemid 28369180)
41. Yoshida K, Sugino K, Tahara H. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-6.
42. Lance, RS, Aldous WK, Blaser J, Thrasher JB. Telomerase activity in solid transitional cell carcinoma, bladder washings, and voided urine. Urol Oncol 1998;4:43-9. (Pubitemid 29131726)
43. Ito H, Kyo S, Kanaya T, et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998;4:2801-10.
44. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4:535-8. (Pubitemid 28193550)
45. Liu BC, Loughlin KR. Telomerase in human bladder cancer. Urol Clin North Am 2000;27(1):115-23. (Pubitemid 30086003)
46. Brentnall TA. Microsatellite instability: shifting concepts in tumorigenesis. Am J Pathol 1995;147:561-3.
47. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-33. (Pubitemid 28416994)
48. Christensen M, Jensen MA, Wolf H, Orntoft TF. Pronounced microsatellite instability in transitional cell carcinomas from young patients with bladder cancer. Int J Cancer 1998;79:396-401. (Pubitemid 28359739)
49. Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835-41. (Pubitemid 29006426)
50. Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62. (Pubitemid 26052913)
51. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 1997;3:621-4. (Pubitemid 27264970)
52. Linn JF, Lango M, Halachmi S, Schoenberg MP, Sidransky D. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997;74:625-9. (Pubitemid 28037506)
53. Mourah S, Cussenot O, Vimont V, et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer 1998;79:629-33. (Pubitemid 28549476)
54. Wang Y, Hung SC, Linn JF, Steiner G, Glazer AN, Sidransky D, Mathies RA. Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers. Electrophoresis 1997;18:1742-9. (Pubitemid 27451828)
55. Klein FA, Herr HW, Sogani PC. Detection and follow-up of carcinoma of the urinary bladder by flow cytometry. Cancer 1982;50:389-95. (Pubitemid 12097403)
56. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study, Diagn Cytopathol 1995;13:214-24.
57. Badalament RA, Kimmel M, Gay H. The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer 1987;59:2078-85. (Pubitemid 17077793)
58. Jankevicius F, Shibayama T, Decken K, Bojar H, Gerharz CD, Ebert T, Ackermann R, Schmitz-Drager BJ. Dual-parameter immunoflow cytometry in diagnosis and follow-up of patients with bladder cancer. Eur Urol 1998;34:492-9. (Pubitemid 28550313)
59. De la Roza GL, Hopkovita A, Caraway NP, Kidd L, Dinney CP, Johnston D, Katz RL. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol 1996;9:571-8. (Pubitemid 26170431)
60. Raitanen MP, Tammela TL, Kalloinen M, Isola J. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997;157:1250-3. (Pubitemid 27130792)
61. Mora LB, Nicosia SV, Pow-Sang JM, et al. Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol 1996;156:49-54.
62. Richman AM, Mayne ST, Jekel JF, Albertsen P. Image analysis combined with visual cytology in the early detection of recurrent bladder carcinoma. Cancer 1998;82:1738-48. (Pubitemid 28208926)
63. Boon ME, Marres EM, van der Poel HG. Combining QUANTICYT karyometric analysis with architectural confocal-aided cytology to prognosticate superficial bladder cancer. Diagn Cytopathol 1998;18:10-7. (Pubitemid 28028658)
64. Matsuyama H, Bergerheim US, Nilsson I, et al. Nonradom numeral aberrations of chromosome 7, 9 and 10 in DNA diploid bladder cancer. Cancer Genet Cytogenet 1994;77:118-24. (Pubitemid 24346074)
65. Sauter G, Gasser TC, Moch H, et al. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 1997;25 Suppl(1):S37-43.
66. Reeder JE, O'Connell MJ, Yang Z, et al. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology 1998;51 (5A Suppl):58-61.
67. Shigyo M, Sugano K, Fukayama N, et al. Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer 1998;78:425-9. (Pubitemid 28481159)
68. Yokogi H, Wabba Y, Moriyama GN, Igawa M, Ishibe T. Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization. Br J Urol 1996;78:699-703. (Pubitemid 27414697)
69. Liebert M, Seigne J. Characteristics of invasive bladder cancers: histological and molecular markers. Sem Urol Oncol 1996;14:62-72. (Pubitemid 26154973)
70. Aprikian AG, Sarkis AS, Reuter VE, Cordon-Cardo C, Sheinfeld J. Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts. Sem Urol 1993;11:137-44. (Pubitemid 23262804)
71. Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 1998;160:1971-4. (Pubitemid 128703594)
72. Pariente JL, Bordenave L, Michael P, Latapie MJ, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997;158:338-41. (Pubitemid 27327662)
73. Sanchez-Carbayo M, Espasa A, Chinchilla V, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 1999;45(11):1944-53. (Pubitemid 29522002)
74. Barton H, Liebert M, Sakakibra N, Wedemeyer G, Stein J, Washington R. Evaluation of new bladder tumor marker. Urol Clin N Am 1991;18:509-13.
75. Huland H, Arndt R, Huland E, Loening T, Steffens M. Monoclonal antibody 486p 3/12: a valuable bladder carcinoma marker for immunocytology. J Urol 1987;137:654-9. (Pubitemid 17058672)
76. Cordon-Cardo C, Wartinger D, Lemaned M, Fair WR, Fradet Y. Immunopathology analysis of human urinary bladder cancer. Am J Pathol 1992;140:375-85.
77. Celis JE, Rasmussen HH, Vorum H, et al. Bladder squamous cell carcinoma expresses psoriasin and externalizes it to the urine. J Urol 1996;155:2105-12. (Pubitemid 26146716)
78. Wilding G, Knabbe C, Zugmaier G, Flanders K. Differential effect of TGF beta on human prostate cancer cells in vitro. Molec Cell Endocrinol 1989;62:79-87. (Pubitemid 19070496)
79. Mian C, Pycha A, Weiner, Haitel A, Lodde M, Marberger M. Immunocyt*: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9. (Pubitemid 29420801)
80. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997;57:773-7. (Pubitemid 27085665)
81. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83. (Pubitemid 27085666)
82. Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;27(1):53-61. (Pubitemid 30085998)
83. Lokeshwar VB, Obek C, Pham HT, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000;163(1):348-56.
84. Chopin DK, Caruelle JP, Colombel M, Palcy S, Ravery V, Caruelle D, Abbou CC, Barritault D. Increased immuno-detection of acidic fibroblast growth factor in bladder cancer detectable in urine. J Urol 1993;150:1126-30. (Pubitemid 23272477)
85. Ravery V, Jouanneau J, Gil Diez S, et al. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol Res 1992;20:211-4.
86. Chow NH, Change CJ, Yeh TM, Chan SH, Tzai TS, Lin JS. Implications of urinary basic fibroblast growth factor excretion in patients with urothelial carcinoma. Clin Science 1996;90:127-33. (Pubitemid 26034718)
87. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85:241-2. (Pubitemid 23046901)
88. Korman HJ, Peabody JO, Cerny JC, Farah RN, Yao J, Raz A. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J Urol 1996;155:347-9. (Pubitemid 126426492)
89. Guirguis R, Schiffmann E, Liu B, Birkbeck D, Engel J, Liotta L. Detection of autocrine motility factor in urine as a marker of bladder cancer. J Natl Cancer Inst 1988;80:1203-11.
90. Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 1994;44:502-6.
91. Mayamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor beta 1 in human bladder cancer. Cancer 1995;75:2565-70.
92. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241-5. (Pubitemid 23223289)
93. Ross JS, del Rosario AD, Figi HL, Sheehan C, Fisher HAG, Bui HX. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol 1995;26:940-4.
94. Ross JS, Cheung C, Sheehan C, del Rosario AD, Bui HX, Fisher HAG. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology. Diagn Cytopathol 1996;14:310-5. (Pubitemid 26177678)
95. Ross JS, del Rosario AD, Bui HX, Kallakury BVS, Okby NT, Figge J. CD44 cell adhesion molecule expression in urinary bladder transitional cell carcinoma. Mod Pathol 1996;9:854-60. (Pubitemid 26279277)
96. Toma V, Hauri D, Schmid U, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 1999;155(5):1427-32.
97. Muller M. Heicappell R, Habermann F, Kaufmann M. Steiner U, Miller K. Expression of CD44v2 in transitional cell carcinoma of the urinary bladder and in urine. Urol Res 1997;25:187-92. (Pubitemid 27252796)
98. Liebert M, Washington R, Stein J, Wedemeyer G, Grossman H. Expression of the DLAb1 integrin family in bladder cancer. Am J Pathol 1994;144:1016-22.
99. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997;158:2098-101. (Pubitemid 27481336)
100. Tsihlias J, Grossman HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000;27(1):39-46. (Pubitemid 30085996)
101. Hsui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogin activator in patients with superficial bladder cancer. Urology 1996;47:34-7. (Pubitemid 26038300)
102. Lafuente A, Rodriguez A, Gibanel R, et al. Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer. Anticancer Res 1998;18:3771-2. (Pubitemid 28564263)
103. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163(3):758-60. (Pubitemid 30091610)
104. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999; 5(12):4079-84. (Pubitemid 30013788)
105. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206. (Pubitemid 28108758)
106. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-40.
107. Caron-Cardo C. Cell cycle regulators as prognostic factors for bladder cancer. Eur Urol 1998;33 (Suppl4):11-2.
108. Wiman KG. p53: Emergency brake and target for cancer therapy. Exper Cell Res 1997;237:14-8. (Pubitemid 27528023)
109. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder carcinoma. N Engl J Med 1994;331:1259-64. (Pubitemid 24333190)
110. Hudson MA, Herr HW. Carcinoma in-situ of the bladder. J Urol 1995;153:564-72.
111. Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000;27(1):75-82. (Pubitemid 30086000)
112. Righi E, Rossi G, Ferrari G, et al. Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol 1997;17:436-9. (Pubitemid 27524447)
113. Phillips HA, Howard GC, Miller WR. p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. Br J Cancer 2000;82(1):136-41. (Pubitemid 30008972)
114. Benedict WF. Altered Rb expression as a prognostic clinical marker involved in human bladder tumorigensis. J Cell Biochem (Suppl) 1992;161:769-71.
115. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-59. (Pubitemid 29479481)